Registered Kenya · PPB

BUTAQUONE 5%

BUPAVARQUONE

What it does

Bupavarquone is a medication used to treat certain infections caused by parasites.

Commonly used for: infections caused by parasites

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
37
Registration date
-
Expiry date
-
Status
Registered
Active ingredient
BUPAVARQUONE
Dosage form
BUPAVARQUONE 50MG
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Vetcare Kenya
Applicant / LTR
-
Country of origin
FOREIGN
Manufacturer location
Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:57:30 · updated 2026-07-26 13:39:42

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Bupavarquone is a medication used to treat certain infections caused by parasites.

What it treats

  • infections caused by parasites

How it works

Bupavarquone works by targeting and killing the parasites that cause the infection.

Who it's for

It is used for individuals diagnosed with specific parasitic infections.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: bupavarquone

Bupavarquone is an investigational drug that is being studied for its potential use as an antiprotozoal agent, particularly for the treatment of certain parasitic infections. It belongs to a class of compounds known for their ability to inhibit mitochondrial function in parasites, leading to cell death. Its specific application is primarily in the context of treating infections caused by pathogens such as Trypanosoma and Leishmania species.

Indications

  • Trypanosomiasis
  • Leishmaniasis
  • Other protozoal infections

Dosage

Children: Refer to clinical guidelines or specific product information for pediatric dosing recommendations.

Adults: Refer to clinical guidelines or specific product information for dosing recommendations.

Mechanism of action

Bupavarquone exerts its effects by inhibiting the mitochondrial respiratory chain in parasites, specifically targeting the cytochrome bc1 complex. This inhibition disrupts the electron transport chain, leading to a decrease in ATP production, which is critical for the survival and replication of the parasitic organisms. This mechanism is similar to that of other antiprotozoal agents that affect mitochondrial function.

Pharmacodynamics

Bupavarquone demonstrates a concentration-dependent killing effect on protozoan parasites. The drug's efficacy is influenced by its ability to accumulate within the mitochondrial environment of the parasites, where it can effectively disrupt energy metabolism. The selectivity for parasitic cells over mammalian cells contributes to its therapeutic potential, though its safety profile is still under investigation.

Pharmacokinetics

The pharmacokinetic properties of bupavarquone are still being characterized in clinical studies. Initial data suggest that it may exhibit moderate oral bioavailability, with variable absorption depending on formulation and food intake. The drug is likely to undergo hepatic metabolism, with metabolites excreted primarily via the urine. The elimination half-life and clearance rates remain to be fully elucidated through ongoing research.

Adverse effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Anorexia
  • Fatigue
  • Headache
  • Dizziness
  • Rash
  • Elevated liver enzymes

Precautions

  • Use with caution in patients with liver impairment
  • Monitor for potential hepatotoxicity
  • Assess for drug interactions with other hepatically metabolized agents

Pregnancy

Bupavarquone should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if bupavarquone is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

  • Oral tablets
  • Injectable solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.